Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.
Brand names: Simlandi
12.1 Mechanism of Action Adalimumab products bind specifically to TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with SIMLANDI may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also mod
Contraindications
8 documented side effects by frequency
7 Reddit threads analysed for ADALIMUMAB-RYVK
Overall Sentiment
Mixed
Comparison Threads
0
Avg Post Score
4 upvotes
Most discussed side effects in community
I’m a 49M Crohn’s veteran, pretty new to Reddit. I’ve been on Humira for the past 10 years with fantastic results. By far the longest remission period since I was diagnosed in 1986. Last summer I had a skin cancer spot on my ear, a basal cell. Had it removed via Moh’s surgery. Now I have another spo
REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Lt
SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira® PARSIPPANY, N.J. & REYKJAVÍK, Iceland--(BUSINESS WIRE)-- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced t
* In October 2024, the U.S. Food and Drug Administration (FDA) approved SELARSDI™ for all indications matching the reference product Stelara® (ustekinumab) and has granted a provisional determination of interchangeability for SELARSDI * SELARSDI is the second biosimilar to launch in the U.S. under t
February 23, 2024 8:15 PM SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for intercha
Alvotech will manufacture its high-concentration interchangeable biosimilar to Humira® (adalimumab) for Quallent Pharmaceuticals The strategic agreement is in alignment with Alvotech’s U.S. commercialization agreement with Teva Pharmaceuticals The high-concentration interchangeable biosimilar to Hum
* Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis * The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection i
Community discussions are sourced from public Reddit threads. Content reflects individual opinions and is not medical advice.
11 available comparisons
Dosage Forms
Tablet
Route
Subcutaneous